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DOI 10.1016/j.ccr.2010.08.009SUMMARYRho GTPases impact a number of activities important for oncogenesis. We describe a small molecule inhib-
itor that blocks oncogenic transformation induced by various Rho GTPases in fibroblasts, and the growth of
human breast cancer and B lymphoma cells, without affecting normal cells. We identify the target of this
inhibitor to be the metabolic enzyme glutaminase, which catalyzes the hydrolysis of glutamine to glutamate.
We show that transformed fibroblasts and breast cancer cells exhibit elevated glutaminase activity that is
dependent on Rho GTPases and NF-kB activity, and is blocked by the small molecule inhibitor. These find-
ings highlight a previously unappreciated connection between Rho GTPase activation and cellular metabo-
lism and demonstrate that targeting glutaminase activity can inhibit oncogenic transformation.INTRODUCTION
Rho-family GTPases activate signaling pathways that influence
a variety of cellular activities ranging from actin cytoskeletal
rearrangements to cell polarity and migration, cell cycle pro-
gression, and membrane trafficking (Etienne-Manneville and
Hall 2002). A number of lines of evidence have also implicated
Rho GTPases in cell growth and malignant transformation
(Vega and Ridley 2008). For example, their hyper-activation
either through mutations or the deregulation of their guanine
nucleotide exchange factors (GEFs; e.g., members of the
diffuse B cell lymphoma [Dbl] family) results in cellular transfor-
mation (Erickson and Cerione, 2004). Cells expressing constitu-
tively active Rho GTPases are able to grow under conditions of
serum deprivation and in the absence of a substratum, and
have been shown to induce tumor formation when introduced
into immunocompromised mice (Lin et al., 1999; Fort, 1999).Significance
The importance of alteredmetabolism in cancer progression is
glutamine metabolism and its role in replenishing citric acid c
formation. We describe a regulatory connection between vario
sheds new light on how glutamine metabolism is elevated duri
inhibitor of oncogenic transformation, by uncoupling this con
formed fibroblasts and human cancer cells, inhibits their grow
bilities regarding the targeting of glutaminase as a potential th
CanRho GTPases have also been implicated in naturally occurring
neoplastic development, where their overexpression has been
demonstrated in advanced stage breast cancers, as well as in
a variety of other cancers (Suwa et al., 1998; Mira et al.,
2000; Fritz et al., 2002; Kamai et al., 2004). In particular, two
members of the family, RhoA and RhoC, have been linked to
the progression of malignancy, i.e., poorly differentiated pheno-
types, local invasiveness, and metastasis (Kleer et al., 2002;
Clark et al., 2000; Burbelo et al., 2004; Valastyan et al., 2009).
Moreover, deleted in liver cancer 1 (DLC1), whose expression
is suppressed in liver cancer tissue and in a wide variety of
other cancers, is a Rho-GTPase-activating protein (Rho-GAP)
and therefore it appears to play a role as a tumor suppressor
(Xue et al., 2008; Lahoz and Hall, 2008). Thus, the Rho GTPases
represent intriguing targets for anticancer therapies. Here we
describe the identification and characterization of a small mole-
cule that blocks the Rho GTPase-dependent transformation ofreceivingmuch attention given the suggestions that elevated
ycle intermediates are essential features of malignant trans-
us Rho GTPases and themetabolic enzyme glutaminase that
ng tumorigenesis. Moreover, we show how a small molecule
nection and blocking the activation of glutaminase in trans-
th and invasive activity. These findings raise exciting possi-
erapeutic strategy against malignant transformation.
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Figure 1. The Small Molecule 968 Inhibits
Cellular Transformation
(A) Left: NIH 3T3 cells were transiently transfected
with oncogenic Dbl and cultured for 14 days in 5%
calf serum, while treated with different benzo[a]
phenanthridinones (designated 384, 335, 968,
537, and 343) (10 mM each). Cells were fixed with
3.7% formaldehyde in PBS and stained with
crystal violet for counting foci. Right: 968 was seri-
ally diluted (10, 5, 2.5, and 1.25 mM) and evaluated
for its ability to inhibit focus formation.
(B) NIH 3T3 cells were stably transfected with Dbl
and grown in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 1% calf
serum and the indicated amounts of 968. After
6 days, the cells were counted. One hundred
percent represents the number of Dbl-trans-
formed cells counted in the absence of 968
(27.5 3 104 cells). Data represent the average of
three experiments (±standard deviation [SD]).
(C) Chemical structures of the benzo[a]phenanthri-
dinone derivatives examined for their effects on
Dbl-induced focus formation (A) and Figure S1B.
(D) Control NIH 3T3 cells were cultured in DMEM
supplemented with 10% calf serum in 6-well
plates, and were either treated with 10 mM 968 or
335, or untreated. At the indicated times, the cells
were counted. Data represent the average of three
experiments (±SD).
(E) Photomicrographs of Dbl-transfected NIH 3T3
cells (bottom panels) and control NIH 3T3 cells
(top panels) cultured in 10% calf serum and
treated with either dimethyl sulfoxide (DMSO)
(vehicle control) or 10 mM 968.
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Rho GTPases Activate Glutaminase in Cancer Cellsfibroblasts, as well as the growth and invasive activity of human
cancer cells.
RESULTS
Identification of an Inhibitor of Rho GTPase-Dependent
Transformation
While screening for small molecule inhibitors of the transforming
capabilities of activated Rho GTPases, we found that members
of the benzo[a]phenanthridinone family blocked the cellular
transformation induced by the Rho family-GEF oncogenic Dbl,
as read-out in focus-forming assays and when assaying cell
growth in 10% calf serum or in low (1%) serum (Figure 1A and
Figures S1A and S1B available online, respectively). The most
effective molecule, designated 968, was active at 1–10 mM208 Cancer Cell 18, 207–219, September 14, 2010 ª2010 Elsevier In(F
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amine and the adjacent bromine substitu-
tion on the phenyl ring of 968 (circled in
Figure 1C) are essential for maximal inhi-
bition of Dbl-induced transformation, as
compounds 335 or 384 showed little or
no effect (Figure 1A and Figure S1B).
The molecule 968 was a more potent
inhibitor of Dbl-induced transformation,
compared to oncogenic H-Ras, when as-
saying focus formation in NIH 3T3 cellsigures S1B and S1C) or growth in low serum (compare
igure 1B and Figure S1D), indicating that the transforming activ-
ies of Rho GTPases are particularly sensitive to this small mole-
ule. Treatment with 968 had no significant effects on the growth
f normal NIH 3T3 cells (Figure 1D) nor did it alter their overall
orphology (Figure 1E).
The guanine nucleotide exchange activities of a number of
hoGTPases are directly stimulated by oncogenic Dbl, including
dc42 andRhoC (Hart et al., 1994); moreover, Rac appears to be
ctivated in cells expressing oncogenic Dbl, most likely as an
utcome of its ability to function in a GTPase cascade down-
tream of activated Cdc42 (Baird et al., 2005). Mutated Rho
TPases that undergo constitutive GDP-GTP exchange mimic
any of the actions of oncogenic Dbl (Lin et al., 1999). Thus,
e used cells transformed by different Rho GTPases to
Figure 2. Effects of 968 on the Transforming
Activity of Constitutively Active Rho
GTPases
(A) NIH 3T3 cells stably expressing hemagglutinin
(HA)-tagged Cdc42(F28L), Rac(F28L), RhoC
(F30L), or vector control cells, either treated with
10 mM 968 or untreated, were grown in soft
agar (plus DMEM supplemented with 10% calf
serum). Top: Relative expression of the HA-tagged
GTPases. Bottom: Cells were scored after 14 days
and plotted as the percentage of the total number
of colonies >50 mm in diameter. Data represent the
average of three experiments (± standard deviation
[SD]).
(B) Cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10%
calf serum with or without 10 mM 968, for 6 days,
and thenwere trypsinizedandcounted.Data repre-
sent the average of three experiments (±SD).
(C) Cells were cultured in DMEM supplemented
with 1% calf serum, treated with 10 mM 968 or
untreated, and counted at the indicated times.
Data represent the average of three experiments
(±SD).
(D) Cells were serum-starved, treated with 10 mM
968 or untreated, and seeded in MilliCell upper
chambers containing growth factor-reduced
Matrigel. After 24 hr at 37C, the migratory cells
were fixed, stained with Giemsa stain, and
counted. Data represent the average of three
experiments (±SD).
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ability to block the signaling activity of a specific target of Dbl,
such as RhoC. In fact, we found that 968 was capable of inhibit-
ing the transforming activity of each of the Rho GTPase mutants
examined, blocking their ability to enable cells to form colonies in
soft-agar (Figure 2A) and to grow to high density (Figure 2B) or in
low serum (Figure 2C), as well as inhibiting their invasive activity
(Figure 2D).
968 Blocks the Transforming Activity of Human Breast
Cancer Cells
Rho GTPases have been shown to be overexpressed and/or
hyperactivated in human breast cancer cells (Kleer et al., 2002;
Burbelo et al., 2004; Valastyan et al., 2009). For example,
RhoA and RhoC are hyperactivated in the highly invasive MDA-
MB231 and SKBR3 breast cancer cell lines compared to normal
human mammary epithelial cells (HMECs) (Figure 3A). In addi-
tion, the growth of these cancer cells in low serum or in soft
agar is severely compromised when RhoA and RhoC levels are
knocked down using small interfering RNAs (siRNAs) (Figures
3B-3E). Given the ability of 968 to inhibit the transformation of
fibroblasts by oncogenic Dbl and different constitutively active
Rho GTPases, we were interested in examining its potential
effects on these human breast cancer cells whose transformedCancer Cell 18, 207–219, Sephenotypes are dependent on Rho
GTPase activity. We found that 968
inhibited their ability to form colonies in
soft agar, as effectively as it blocked
Dbl-induced colony formation in NIH 3T3cells (Figure 4A). Similarly, 968 inhibited their growth in complete
medium (Figure 4B), as well as their ability to grow to high density
(Figure 4C) and in low serum (Figure 4D), and reduced their inva-
sive activity (Figure 4E). As was the case for control (nontrans-
formed) fibroblasts, 968 had little if any effect on the growth or
morphology of HMECs (Figures 4C, 4F, and 4G).
Identification of the Target for 968
The ability of 968 to inhibit the transforming activities of different
constitutively active Rho GTPases indicated that the target for
this small molecule was not a specific binding partner or an
effector for an individual Rho protein. We set out to identify the
target for 968 by using its active moiety (circled in Figure 1C)
labeled with biotin in affinity precipitation experiments with
streptavidin beads. This led to the detection of a silver-stained
band on SDS-gels, Mr 66 kDa, that was isolated from Cdc42
(F28L)-expressing NIH 3T3 cell lysates with the biotin-labeled
968-derivative immobilized to streptavidin beads, but not with
beads alone (Figure S2A). Microsequence analysis indicated
that this was the mouse isoform-2 ortholog of human gluta-
minase C (GAC) (Figure S2B), one of two splice variants of an
enzyme found in kidney and other tissues, collectively referred
to as kidney-type glutaminase (KGA), that catalyzes the hydro-
lysis of glutamine to glutamate and ammonium (Curthoys,ptember 14, 2010 ª2010 Elsevier Inc. 209
Figure 3. Rho GTPases Are Hyperactivated
and Are Important for the Growth of Breast
Cancer Cells
(A) Lysates from MDA-MB231 cells, SKBR3 cells,
and human mammary epithelial cells (HMECs),
were prepared and incubated with GST fused to
the limit Rho-binding domain on Rhotekin (GST-
RBD). The top panels show the relative levels of
RhoA-GTP and RhoC-GTP that were coprecipi-
tated with GST-RBD from the indicated cells, as
detected by western blotting with an anti-RhoA
monoclonal antibody and an anti-RhoC polyclonal
antibody. The middle panels compare the relative
expression of RhoA and RhoC in whole cell lysates
(WCL) from the different cells and the bottom panel
shows the relative input of GST-RBD.
(B) MDA-MB231 cells were transfected with con-
trol small interfering RNA (siRNA) or siRNAs target-
ing RhoA and RhoC. Top: Shown are the efficien-
cies of the siRNAs targeting RhoA and RhoC as
assessed by western blot analysis using anti-
RhoA and anti-RhoC antibodies. Bottom: Cells
were grown for the indicated number of days in
RPMI 1640 medium supplemented with 1% fetal
bovine serum and counted. Data represent the
average of three experiments (mean ± standard
deviation [SD]).
(C) MDA-MB231 cells transfected with control
siRNA or siRNAs targeting RhoA and RhoC were
grown in soft agar and scored after 10 days. Histo-
grams show the percentage of the total number of
colonies >50 mm in diameter. Data represent the
average of three experiments (mean ± SD).
(D) SKBR3 cells were transfected with control
siRNA or siRNAs targeting RhoA and RhoC. Top:
Shown are the efficiencies of the siRNAs targeting
RhoA and RhoC. Bottom: Cells were grown in
RPMI 1640 medium supplemented with 1% fetal
bovine serum for the indicated number of days
and counted. Data represent the average of three
experiments (mean ± SD).
(E) SKBR3 cells transfected with control siRNA or
siRNAs targeting RhoA and RhoC were grown in
soft agar and scored after 10 days. Histograms
show the percentage of the total number of colo-
nies >50 mm in diameter. Data represent the
average of three experiments (mean ± SD).
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when immobilized on streptavidin beads, affinity-precipitated
an endogenous protein that reacted with an antibody recog-
nizing both isoforms of KGA (Figure S2C), as well as precipitated
ectopically expressed, V5-tagged GAC (Figure 5A, top panel).
Preincubation of Escherichia coli-expressed, mouse GAC with
968 inhibited its enzyme activity (Figure 5A), whereas the struc-
turally-related compound 335, that was less effective at blocking
Dbl-transformation (Figure 1A), showed little inhibition. 968 was
neither a competitive inhibitor versus glutamine nor inorganic
phosphate, an activator of the enzyme (Kenny et al., 2003), sug-
gesting that it acts in an allosteric manner (Figures S2D–S2F).
We next examined whether knocking down the levels of
KGA expression in transformed cells using RNA interference
(RNAi) mimicked the effects of treating these cells with 968.
Figure 5B and Figure S3A show that reducing KGA expression
by using siRNAs targeting both of its isoforms inhibited the210 Cancer Cell 18, 207–219, September 14, 2010 ª2010 Elsevier Inabilities of Cdc42(F28L), Rac(F28L), and RhoC(F30L) to stimulate
growth in low serum. Similarly, knocking down KGA expression
blocked the ability of these different constitutively activated Rho
GTPases to induce colony formation in soft agar (Figures 5C
and Figure S3B), whereas knock downs of KGA did not signifi-
cantly inhibit the growth of control NIH 3T3 cells (Figure S3C),
consistent with the inability of 968 to affect their growth (Fig-
ure 1D). However, knocking down KGA also strongly inhibited
MDA-MB231 and SKBR3 cells from growing in low serum
(Figure 5D) and soft-agar (Figure 5E).
The importance of glutaminase activity for transformation is
consistent with the dependence of transformed/cancer cells on
extracellular glutamine (Figures 6A and 6B). We reasoned that
if 968 blocks transformation by inhibiting glutaminase activity,
it should also reduce the levels of a-ketoglutarate, an interme-
diate in the glutamine metabolic pathway. Therefore, the effects
of 968 should be circumvented by adding a cell-permeablec.
Figure 4. Effects of 968 on the Growth and Invasive Activity of Human Breast Cancer Cells
(A) MDA-MB231 cells, SKBR3 cells, and NIH 3T3 cells stably expressing Dbl, were either treated with 10 mM 968 or untreated, and grown in soft-agar as in
Figure 2A. Data represent the average of three experiments (±standard deviation [SD]).
(B) MDA-MB231 and SKBR3 cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum in 12-well plates for the indicated number of
days in the presence or absence of 10 mM 968, and then counted. Data represent the average of three experiments (±SD).
(C) Breast cancer cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum, and human mammary epithelial cells (HMECs) were
cultured in mammary epithelial cell growth complete medium (MEGM) in 12-well plates, for 6 days in the presence or absence of 10 mM 968, and counted.
Data represent the average of three experiments (±SD).
(D) Breast cancer cells were cultured in RPMI 1640 medium supplemented with 1% fetal bovine serum, treated with 10 mM 968 or untreated, and counted at the
indicated times. Data represent the average of three experiments (±SD).
(E) Breast cancer cells were serum-starved, treated with 968 or untreated, and seeded in MilliCell upper chambers containing growth-factor-reduced Matrigel.
After 24 hr at 37C, the migratory cells were fixed, stained with Giemsa stain, and counted. Data represent the average of three experiments (±SD).
(F) HMECs were cultured in MGEM in 12-well plates for the indicated number of days in the presence and absence of 10 mM 968, and then counted.
(G) Photomicrographs of HMECs cultured in MGEM treated with either DMSO (vehicle control) or 10 mM 968.
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Figure 5. Glutaminase Serves as a Target
for 968
(A) The Escherichia coli-expressed mouse ortho-
log of human GAC was preincubated with the indi-
cated amounts of 968 (filled circles) or 335 (open
circles) for 30 min at 37C and then assayed.
100% = 620 mol of glutamine hydrolyzed per
minute per mol of enzyme. Data represent the
average of three experiments (±standard deviation
[SD]). Top panel: The biotin-labeled, active moiety
of 968 linked to streptavidin-agarose beads, or
control beads alone, were incubated with NIH
3T3 cell lysates transiently expressing V5-tagged
mouse GAC. After precipitation of the beads and
resuspension, the samples were analyzed by
western blotting with anti-V5 antibody.
(B) NIH 3T3 cells stably expressing HA-Cdc42
(F28L), cells stably expressing HA-Cdc42(F28L)
transfected with control small interfering RNA
(siRNA) or siRNAs targeting both isoforms of
mouse kidney-type glutaminase (KGA), or control
cells, were grown in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 1% calf
serum. Top: Efficiencies of siRNAs targeting both
isoforms of KGA, and relative levels of HA-Cdc42
in the different cells. Bottom: Growth profiles for
the indicated cell lines. Data represent the average
of three experiments (±SD).
(C) NIH 3T3 cells stably expressing Cdc42(F28L),
cells stably expressing Cdc42(F28L) transfected
with control siRNA or siRNAs targeting both
isoforms of mouse KGA, and control (vector) cells,
were grown in soft agar and scored after 10 days.
Histograms show the percentage of the total
number of colonies >50 mm in diameter. Data
represent the average of three experiments
(mean ± SD).
(D) Breast cancer cells transfected with control
siRNA or siRNAs targeting both isoforms of KGA
were grown in RPMI 1640 medium supplemented
with 1% fetal bovine serum. Top: Efficiencies of
siRNAs targeting both isoforms of KGA. Bottom:
Growth profiles for the indicated cell lines. Data
represent the average of three experiments (±SD).
(E) The indicated breast cancer cell lines were
transfected with control siRNA or with siRNAs tar-
geting both isoforms of KGA and then grown in
soft agar and scored after 10 days. Data represent
the average of three experiments (mean ± SD).
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to cells. Figure 6C shows that when the KGA isoforms were
knocked down from Dbl-transformed cells, the addition of DM-
a-KG restored their ability to grow in low serum. Likewise, the
addition of DM-a-KG restored the ability of 968-treated Dbl-cells
to grow in low serum (Figure 6D) and their focus-forming activity
(Figure 6E), as well as the ability of 968-treatedMDA-MB231 and
SKBR3 cells to grow in low serum (Figures 6F and 6G).212 Cancer Cell 18, 207–219, September 14, 2010 ª2010 Elsevier Inc.The expression of the KGA isoform
GAC is upregulated in P-493 B lymphoma
cells (Gao et al., 2009), which prompted
us to examine the effects of 968 on these
cancer cells. Figures 7A and 7B show that968 inhibited their growth, whereas the inactive analog 335 had
essentially no effect. Similarly, in mouse xenograft experiments
where tumors were induced by the introduction of P-493 B
lymphoma cells, the intra-peritoneal injection of 968 caused an
50% reduction in the size of the tumors (Figure 7C). However,
the overexpression of GAC, alone, is not sufficient to induce
malignant transformation (Gao et al., 2009). Moreover, gluta-
minase expression in Dbl-transformed fibroblasts or in SKBR3
Figure 6. The Relationship between the Glutamine Dependence of Transformed/Cancer Cells and Their Sensitivity to 968
(A) MDA-MB231 cells and SKBR3 cells were grown in 10% fetal bovine serum in the presence or absence of glutamine for the indicated number of days and
counted.
(B) NIH 3T3 cells stably expressing Dbl and cells stably expressing Cdc42(F28L) were grown in 10% calf serum in the presence or absence of glutamine for the
indicated number of days and counted.
(C) NIH 3T3 cells stably expressing HA-tagged Dbl alone, and cells stably expressing HA-Dbl that were transfected with control small interfering RNA (siRNA) or
siRNAs targeting both isoforms of kidney-type glutaminase (KGA), were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 1% calf
serum in the presence and absence of 7 mM dimethyl a-ketoglutarate (DM-a-KG). Top: Efficiencies of siRNAs targeting both isoforms of KGA, and relative levels
of HA-Dbl in the different cells. Bottom: Growth profiles for the indicated cell lines. Data represent the average of three experiments (±SD).
(D) NIH 3T3 cells stably expressing Dbl were cultured in DMEM supplemented with 1% calf serum in the presence of 10 mM 968 alone or together with 7 mM
DM-a-KG. Data represent the average of three experiments (±SD).
(E) NIH 3T3 cells transiently expressing Dbl were assayed for focus formation in the presence of 10 mM 968 alone or together with 7 mM DM-a-KG.
(F) MDA-MB231 cells were grown in 1% fetal bovine serum in the presence of 10 mM968 alone or together with 7 mM dimethyl a-ketoglutarate (DM-a-KG) for the
indicated number of days and counted. Data represent the average of three experiments (mean ± SD).
(G) SKBR3 cells were grown in 1% fetal bovine serum in the presence of 10 mM 968 alone or together with 7 mM dimethyl a-ketoglutarate. Data represent the
average of three experiments (±SD).
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Figure 7. Effects of 968 on B Lymphoma
Cells and Cdc42(F28L)-Transformed Cells
Overexpressing GAC
(A) P493 B lymphoma cells were cultured in RPMI
1640medium supplemented with 10% fetal bovine
serum in the presence of the indicated concentra-
tions of 968.
(B) P493 B lymphoma cells were cultured in RPMI
1640medium supplemented with 10% fetal bovine
serum in the presence of the inactive 968-analog
335.
(C) P493 B lymphoma cells (23 107) were injected
subcutaneously into the flank of SCID mice. At day
12 the tumors were170mm3, at which time treat-
ments with 968 (200 mg per injection) were begun
by daily intraperitoneal injections (200 mL) for
12 days. Control animals were treated with vehicle
(DMSO in PBS). n = 7. The p value on day 24 =
0.000375.
(D) Left: Control NIH 3T3 cells, NIH 3T3 cells tran-
siently expressing Dbl, cells stably expressing
Cdc42(F28L) and transiently expressing mouse
GAC, cells stably expressing Cdc42(F28L), cells
transiently expressing GAC, and cells stably
expressing Cdc42(F28L) and transiently express-
ing Dbl, were examined for focus-forming activity.
Right: Quantification of foci. Data represent the
average of three experiments (±standard deviation
[SD]).
(E) Left: Focus-forming assays carried out on NIH
3T3 cells stably expressing Cdc42(F28L), cells
stably expressing Cdc42(F28L) and transiently ex-
pressing Dbl, and cells stably expressing Cdc42
(F28L) and either transiently expressing wild-type
mouse GAC or the GAC(S291A) mutant. Right:
Quantification of foci. Data represent the average
of three experiments (±SD).
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below), suggesting that GAC works together with other onco-
genic proteins to satisfy the metabolic requirements for transfor-
mation. This is supported by the results in Figure 7D, in which the
transient expression of GAC alone, in NIH 3T3 cells was insuffi-
cient to induce foci, whereas the expression of GAC in cells
stably expressing the Cdc42(F28L) mutant, which exhibits only
weak focus-forming activity, caused a dramatic increase in foci
matching the strong response induced by oncogenic Dbl. The
increase in foci accompanying the expression of GAC together
with Cdc42(F28L) was blocked by 968 (Figure 7D) and did not
occur when the catalytically dead GAC(S291A) mutant was
coexpressed with Cdc42(F28L) (Figure 7E).
GlutaminaseActivity Is Elevated in Transformed/Cancer
Cells
Given that glutaminase is not overexpressed in transformed
fibroblasts or SKBR3 cells, we examined whether it is activated
in these cells. Indeed, mitochondrial preparations from Dbl-
transformed fibroblasts exhibited much higher basal gluta-
minase activity (i.e., assayed in the absence of inorganic
phosphate) compared to the activity in mitochondria from non-
transformed NIH 3T3 cells (Figure 8A; p = 0.001). Mitochondria
from Cdc42(F28L)-expressing cells showed lower basal levels214 Cancer Cell 18, 207–219, September 14, 2010 ª2010 Elsevier Inof activity compared to Dbl-transformed cells (p value = 0.019),
but still higher than nontransformed cells (p = 0.023). Rac
(F28L)- and RhoC(F30L)-transformed cells also showed higher
basal levels of mitochondrial glutaminase activity compared to
control cells (p = 0.019 and 0.009, respectively). The enzyme
activity in mitochondrial preparations from control cells was
strongly stimulated by the addition of inorganic phosphate
(6-fold), approaching the phosphate-stimulated activity mea-
sured in the mitochondria from transformed cells (Figure S4A),
consistent with these two sets of cells showing similar levels of
enzyme expression. Treatment of the different transformed cells
with 968 inhibited their mitochondrial glutaminase activity, with
the basal enzyme activity beingmuchmore sensitive to the small
molecule inhibitor than the phosphate-stimulated activity
(Figure 8A and Figure S4A).
Mitochondrial preparations fromSKBR3 cells, aswell asMDA-
MB231 cells, also showed significantly higher basal glutaminase
activity, compared to normal HMECs (p = 0.003), that was
strongly inhibited when the cells were treated with 968 (Fig-
ure 8B; the top panels show that equivalent amounts of mito-
chondrial protein were assayed, by using the mitochondrial
marker voltage-dependent anion channel [VDAC]/porin). The
addition of inorganic phosphate to the mitochondrial prepara-
tions from HMECs caused a marked increase in glutaminasec.
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lower than in MDA-MB231 cells that show significantly higher
KGA expression (Figure 8B, top panel), they were similar to the
phosphate-stimulated activity in the mitochondria from SKBR3
cells (Figure S4B). Knock downs of RhoA and RhoC in SKBR3
cells reduced their basal glutaminase activity, without signifi-
cantly affecting phosphate stimulation of the enzyme, indicating
that the increased basal activity was Rho GTPase-dependent
(Figure S4C).
An important insight into how glutaminase is activated in trans-
formed fibroblasts and SKBR3 cells came from our finding that
treatment of these cells with BAY 11-7082, which blocks
NF-kB activation by inhibiting the upstream kinase IKKb (Picker-
ing et al., 2007), significantly reduced their basal glutaminase
activity (Figures 8C and 8D, respectively). Knocking down the
p65/RelA subunit of NF-kB in Dbl-transformed cells and
SKBR3 cells also reduced their basal glutaminase activity (Fig-
ures 8C and 8D), whereas treatment with BAY11-7082 or knock
downs of p65/RelA had little or no effect on the direct stimulation
of the enzyme by inorganic phosphate (Figures S4and S4E). This
indicates that the effects of blocking NF-kB are specific for those
signals in transformed/cancer cells that elevate the basal levels
of enzyme activity.
We then showed that the immunoprecipitation of ectopically
expressed, V5-tagged GAC from Dbl-transformed cells yielded
significantly higher basal activity compared to V5-GAC immuno-
precipitated from nontransformed NIH 3T3 cells (Figure 8E). The
activity immunoprecipitated from Dbl-transformed cells was
reduced when the cells were treated with 968, as well as with
an NF-kB inhibitor, suggesting that V5-GAC was activated in
transformed cells through an NF-kB-dependent mechanism.
The enhanced basal activity for V5-GAC immunoprecipitated
from Dbl-cells was reversed by alkaline phosphatase treatment,
whereas the stimulation by inorganic phosphate was essentially
unaffected (Figure 8F). These findings suggest that NF-kB does
not elevate basal glutaminase activity in transformed/cancer
cells by directly affecting the expression of the enzyme itself,
but rather by influencing the expression of a protein kinase or
a regulatory protein(s) that promotes its phosphorylation.
DISCUSSION
The importance of bioenergetics and cellular metabolism in the
development of cancer, and in particular, the early observations
that tumor cells exhibit elevated glycolytic activity (i.e., the ‘‘War-
burg effect’’) (Warburg, 1956), are receiving renewed attention
(DeBerardinis et al., 2007; Christofk et al., 2008a, 2008b).
Recently, it was found that phospho-tyrosine signaling impacts
the glycolytic pathway by shifting the utilization of glucose
metabolites from energy production to anabolic processes
through the regulation of the M2 (fetal) isoform of pyruvate
kinase, an enzyme that catalyzes the conversion of phospho-
enolpyruvate to pyruvate (Christofk et al., 2008a, 2008b; Hitosugi
et al., 2009). It was also recently reported that the c-Myc-
induced upregulation of GAC expression in B lymphoma and
prostate cancer cells is essential for their proliferation and
survival (Gao et al., 2009). Here we demonstrate that trans-
formed/cancer cells dependent on Rho GTPase-signaling
activity exhibit elevated levels of basal glutaminase activity andCanthat blocking the activation of this enzyme can have profound
consequences for oncogenic transformation.
The discovery that glutaminase activity is required for the
transforming capability of at least three different Rho GTPases
(Cdc42, Rac1, RhoC) suggests that these GTPases are linked
to the activation of this enzyme through a common signaling
point of convergence. Our finding that NF-kB is essential for
glutaminase activation in transformed/cancer cells helps to
explain how different RhoGTPases are able to signal an increase
in basal glutaminase activity andwhy their transforming activities
are sensitive to 968, as NF-kB is activated by Dbl and various
Rho GTPases (Perona et al., 1997; Cammarano and Minden,
2001), and is essential for Dbl-transformation (Whitehead et al.,
1999) as well as for the transformed phenotypes of human breast
cancer cells (Sovak et al., 1997). The mechanism by which
NF-kB mediates the activation of this metabolic enzyme, and
in particular its phosphorylation, is an important focus of our
current studies. The fact that cells treated with 968 do not exhibit
elevated basal levels of glutaminase activity suggests that this
small molecule acts in an allosteric manner to block the activa-
tion event, thus explaining how its inhibitory effects are sustained
through the isolation of mitochondrial fractions from trans-
formed/cancer cells. The ability of 968 to act in an allosteric
manner is also consistent with our kinetic studies that demon-
strate that 968 is neither a glutamine antagonist nor an active
site competitive inhibitor, and likely explains why its effects
appear to be much more pronounced on transformed/cancer
cells compared to normal cells.
Recently, it has been shown that the expression of a distinct
form of glutaminase, referred to as the liver-type enzyme or
GLS2, was substantially decreased in liver cancer cells and
that its overexpression reduced colony formation (Hu et al.,
2010; Suzuki et al., 2010). The liver-type enzyme has different
kinetic and molecular characteristics, and is likely to be subject
to distinct modes of regulation and cellular actions compared
to the kidney-type enzymes (i.e., collectively referred to as
KGA or also GLS1), whose GAC isoform was originally identified
as the target of 968. Moreover, it is possible that the liver-type
enzyme is exerting its effects in liver cancer cells through its
potential ability to influence transcription (Szeliga et al., 2009),
a function that has not been ascribed to the KGA isoforms.
How the regulation of glycolysis in the cytoplasm and oxidative
metabolism through the citric acid cycle in the mitochondria is
balanced so that tumor cells are able to satisfy their energy
requirements and metabolic needs is not entirely understood.
13C-NMR metabolic flux experiments have demonstrated that
whereas proliferating cancer cells exhibit a pronouncedWarburg
effect, their TCA cycle remains intact and becomes progres-
sively more dependent on glutamine metabolism (DeBerardinis
et al., 2007). This may enable cancer cells to use TCA cycle inter-
mediates as precursors for biosynthetic pathways (DeBerardinis
et al., 2008), and is consistent with tumor cells exhibiting
increased rates of glutamine metabolism and consuming greater
amounts of glutamine compared to normal cells (Medina et al.,
1992). The observation that different transformed cell lines and
cancer cells show elevated glutaminase activity that is depen-
dent on Rho GTPase/NF-kB-activation provides a mechanism
for how these demands for elevated glutamine metabolism are
met. Moreover, the ability of the small molecule 968 to blockcer Cell 18, 207–219, September 14, 2010 ª2010 Elsevier Inc. 215
Figure 8. Role of Glutaminase Activity in Cellular Transformation
(A) Mitochondrial fractions were prepared from equivalent numbers of control NIH 3T3 cells and cells stably expressing Dbl, Cdc42(F28L), Rac(F28L), or RhoC
(F30L) that had been treated with 10 mM968 or untreated. Top: Relative amounts of kidney-type glutaminase (KGA) in the different mitochondrial preparations as
assessed using an antibody that recognizes both KGA isoforms. Bottom: The different mitochondrial fractions were assayed for basal glutaminase activity.
100% = 680 nM glutamine hydrolyzed per minute per 105 cells. Data are the average of three experiments (±standard deviation [SD]).
(B) Mitochondrial fractions were prepared from equivalent numbers of the indicated breast cancer cells that had been treated with 10 mM 968 or untreated. Top:
Relative amounts of KGA and voltage-dependent anion channel (VDAC) in the mitochondrial preparations. Bottom: The different mitochondrial fractions were
assayed for basal glutaminase activity. 100% = 750 nM glutamine hydrolyzed per minute per 105 cells. Data represent the average of three experiments (±SD).
(C) Mitochondrial fractions fromNIH 3T3 cells stably expressing Dbl that were cultured for 2 days in the presence or absence of 2 mMBAY 11-7082, or transfected
with control small interfering RNA (siRNA) or siRNAs targeting p65/RelA. Top: Relative amounts of KGA in the mitochondria from the indicated cells as assessed
using an antibody that recognizes both KGA isoforms, and relative efficiencies of two siRNAs targeting p65/RelA. Bottom: The basal glutaminase activity for the
differentmitochondrial fractions. One hundred percent represents the activity for untreated Dbl-transformed cells. Data represent the average of two experiments
(±range).
(D) Mitochondrial fractions were prepared from human mammary epithelial cells (HMECs), and SKBR3 cells that had been treated with 2 mM BAY 11-7082 or
untreated, or transfected with siRNAs targeting p65/RelA. Top: Relative amounts of KGA in the different mitochondrial fractions as assessed using an antibody
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cancer cells highlights the potential of this enzyme as a drug-
gable target and offers intriguing possibilities regarding the use
of small molecule allosteric inhibitors of glutaminase as thera-
peutic strategies against cancer.
EXPERIMENTAL PROCEDURES
Cell Culture and Treatment with 968
NIH 3T3 cells stably expressing Cdc42(F28L), RhoC(F30L), Rac(F28L), Ras
(G12V), and oncogenic Dbl were cultured in DMEM supplemented with 10%
calf serum (Invitrogen). Two types of human breast cancer cells, MDA-
MB231 and SKBR3 cells, were cultured in RPMI 1640 medium supplemented
with 10% FBS. Normal HMECs were cultured in mammary epithelial cell
growth complete medium (MEGM; Lonza). The small molecule 968 (10 mM)
was added to the culture medium 5 hr after the cells were seeded. The cells
were then treated with 968 during various assays for cellular transformation.
Assays for Cellular Transformation and Invasion
The detailed procedures for cellular transformation assays including growth in
low serum, saturation density, and colony formation in soft agar were carried
out as previously described (Wang et al., 2005; Feng et al., 2006). When assay-
ing cell growth in low serum, or saturation density, the medium containing 968
was changed every 2 days. These changes were carried out every 3 days when
assaying cell growth in soft agar.
Focus formation assays were carried out with NIH 3T3 cells that were grown
in 60-mm plates and transiently transfected with 1 mg pZip-neo-GST-Dbl (in
which the original construct of oncogenic Dbl, residues 498–925, was obtained
from Dr. A. Eva, Genoa, Italy) or 2 mg pCDNA 3.1-V5-glutaminase (i.e., the
mouse ortholog of the human GAC isoform). In some cases, these transient
transfections were carried out using NIH 3T3 cells that stably express Cdc42
(F28L). After transfection, the cells were trypsinized, aliquoted equally into
two 60-mm plates, and allowed to adhere overnight. On the following day,
the media was changed to DMEM + 5% calf serum, or DMEM + 5% calf serum
and 968. A 60-mm plate of NIH 3T3 cells, or cells stably expressing Cdc42
(F28L), was left untreated as a negative control. All cells were then grown for
14 days, with media and compounds changed every second day. Plates
were fixed in 3.7% formaldehyde and stained with 0.4% crystal violet.
For cell invasion assays, growth factor-reduced Matrigel (BD Bioscience)
was diluted (30 mg in 100 ml sterile H2O), added to the top chamber (MilliCell)
and allowed to gel for 1 hr at 37C, and then air-dried for 16 hr. Serum-starved
cells were added to the upper compartment in migration medium (DMEM with
0.5%BSA) and the chamber was placed into 24-well dishes containing DMEM
with 10% CS. After 24 hr incubation at 37C, migratory cells were fixed with
methanol, stained with Giemsa and counted under the microscope.
Animal Studies
The experiments with mouse xenografts were carried out according to the
protocols approved by the Animal Care and Use Committees at Cornell
University and The Johns Hopkins University. In these experiments, 2 3 107
P493 human lymphoma B cells were injected subcutaneously into male
SCID mice (National Cancer Institute). When the tumor volumes reached
170 mm3, intraperitoneal injections with 968 or vehicle control were initiated
and carried out daily for 12 days. Tumor volumes were calculated for the indi-
vidual days of treatment as described by Le et al. (2010).
Identification of Glutaminase as the Target of 968
The molecule 968 (5-[3-bromo-4-(dimethylamino)phenyl]-2,2-dimethyl-
2,3,5,6-tetrahydrobenzo[a]) and its analogs were obtained from SPECSthat recognizes both KGA isoforms, and relative efficiencies of two siRNAs targ
chondrial fractions. One hundred percent represents the activity for untreated SK
(E) Top: V5-GACwas transiently expressed in control NIH 3T3 cells or NIH 3T3 cel
968, or untreated, and then immunoprecipitated from the different samples. Botto
represent the average of three experiments (±SD).
(F) V5-GACwas transiently expressed in NIH 3T3 cells stably expressing Dbl. The
37C (or untreated), and assayed for activity in the presence and absence of pho
Can(Netherlands; CAS). To identify the molecular target of 968, its active moiety
(3-bromo-4-(dimethylamino)benzaldehyde) (ChemBridge, San Diego, CA)
was incorporated into biotin hydrazide by reacting 3-bromo-4-(dimethyla-
mino)benzaldehyde or formaldehyde (as a negative control) at a 5-fold molar
excess overnight at 42C, followed by reduction with cyanoborohydride
coupling buffer. The 968-biotin adduct was confirmed by mass spectrometry
and incubated with streptavidin-agarose beads equilibrated with cell lysis
buffer (5 mM MgCl2, 120 mM NaCl, 10 mM HEPES, pH 7.4, 0.5% NP-40,
10 mg/ml leupeptin, and 10 mg/ml aprotinin) before incubation with lysates
from NIH 3T3 cells stably expressing Cdc42(F28L) (5 ml containing 2 mg/
ml total protein) for 2 hr at 4C. The beads were washed 33 with cold lysis
buffer and pelleted by centrifugation and the associated proteins were
resolved by SDS-PAGE. A silver-stained protein band that bound specifically
to the 968-biotin beads and not to the control beads was excised and analyzed
bymass spectrometry at the HarvardMicrochemistry Facility (Cambridge,MA)
and identified as mouse KGA isoform-2 (accession number NP_001106854),
the mouse ortholog of the human GAC isoform.
Mitochondrial Preparations
Mitochondrial preparations were obtained using the mitochondria isolation kit
fromQIAGEN following themanufacturer’s instructions. A suspension contain-
ing 2 3 107 cells was transferred into a 50-ml conical tube and centrifuged at
500 3 g for 10 min at 4C. The pellets were resuspended in 2 ml of ice-cold
lysis buffer (QIAGEN) and incubated for 10 min at 4C using an end-over-
end shaker. The lysates were centrifuged at 1000 3 g for 10 min at 4C, and
the pellets were resuspended in a buffer supplied by themanufacturer and dis-
rupted by using a blunt-ended, 23-gauge needle and a syringe, followed by
centrifugation at 6000 3 g for 20 min at 4C. The pellets were resuspended
in 100 ml of 20 mM HEPES, pH 7.4, 150 mM NaCl, 1% NP-40, 20 mM b-glyc-
erol-phosphate, 1 mM sodium orthovanadate, and 20 mM sodium fluoride,
and assayed for activity as previously described (Kenny et al., 2003) and out-
lined below for assaying recombinant enzyme, except that the recombinant
protein was replaced by 20 ml of resuspended mitochondrial lysate.
RNAi
The knock down of KGAwas carried out using two distinct Stealth Select RNAi
duplexes (Invitrogen) directed against the two forms of the kidney-type
enzyme. The RNAi nucleotides were transiently transfected in either control
NIH 3T3 cells and NIH 3T3 cells stably expressing Cdc42(F28L), Rac(F28L),
RhoC(F30L), MDA-MB231 cells, or SKBR3 cells using Lipofectamine 2000
and the relative knock down efficiency was determined using a polyclonal
antibody that recognizes both forms of KGA (a kind gift from Dr. N. Curthoys,
Colorado State University). A nonspecific oligonucleotide was used as a nega-
tive control. Knock-downs of RhoA, RhoC, and p65/RelA were carried out with
siRNAs obtained from Invitrogen and their efficiencies were determined using
anti-RhoC polyclonal antibody (Santa Cruz), and an anti-RhoA monoclonal
antibody and an anti-p65/RelA polyclonal antibody (Cell Signaling).
Assays of Recombinant Glutaminase Activity
Glutaminase activity assays were carried out on recombinant enzyme as previ-
ously described (Kenny et al., 2003). A plasmid encoding mouse GAC (resi-
dues 128–603) was cloned into the pET28a vector and the protein was
expressed with an N-terminal histidine (His)-tag. The tag was cleaved using
thrombin and the protein was purified by anion-exchange and gel-filtration
chromatography. Recombinant GAC (1 mM) was incubated with varying
concentrations of 968 in 57 mM Tris-acetate (pH 8.6) and 0.225 mM ethylene-
diaminetetraacetic acid by rotating at 37C for 30min, in a final volume of 80 ml.
The molecule 968 was diluted in dimethyl sulfoxide (DMSO) such that the
volume added was constant (5 ml) for all samples, ensuring that theeting p65/RelA. Bottom: The basal glutaminase activity for the different mito-
BR3 cells. Data represent the average of two experiments (±range).
ls stably expressing Dbl that were treated with either 2 mMBAY 11-7082, 10 mM
m: Basal activity for V5-GAC immunoprecipitated from the different cells. Data
V5-GACwas immunoprecipitated, treated with alkaline phosphatase for 1 hr at
sphate.
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Rho GTPases Activate Glutaminase in Cancer Cellsconcentration of DMSO (6.3% v/v) was the same in each of the assay incuba-
tions. A glutamine solution was then added to give a final volume of 115 ml and
a final concentration of 17 mM. The reaction proceeded at 37C for 1 hr and
was stopped by adding 10 ml of ice-cold 3M hydrogen chloride (HCl). An
aliquot of the quenched reaction mixture (10 ml) was added to an incubation
containing 114 mM Tris-HCl (pH 9.4), 0.35 mM adenosine diphosphate
(ADP), 1.7 mM nicotinamide adenine dinucleotide (NAD), and 6.3 U/ml gluta-
mate dehydrogenase to give a final volume of 228 ml. The reaction mixture
was incubated at room temperature for 45 min and the absorbance at
340 nm was recorded for each sample against a water blank. The absorbance
of the sample with just the cocktail mixture was subtracted from each reading
to calculate the activity of the enzyme.
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